The secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily life is seriously impaired, and they may become severely depressed. SandostatinR alleviates the condition by inhibiting peptide release, and its long duration of action makes it an effective and rational adjunct to therapy at all stages. Last year a consensus Round Table Meeting was held in Scottsdale, Arizona, to discuss the optimal use of SandostatinR in this indication. These guidelines offer the results of clinical research and the dosage recommendations arising from them, together with a critical summary of the points of view presented.
Sprache
Verlagsort
Verlagsgruppe
Illustrationen
Dateigröße
ISBN-13
978-3-642-61328-9 (9783642613289)
DOI
10.1007/978-3-642-61328-9
Schweitzer Klassifikation
1. Prologue.- 2. Chemical Structure - Pharmacological Profile of Sandostatin®.- 3. Carcinoid Tumours and the Carcinoid Syndrome.- 4. Tumors of the Gastroentero-pancreatic Axis.- 5. The Use of Sandostatin® in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis.- 6. Sandostatin®: Assay and Efficacy in VIPoma and Insulinoma.- 7. Sandostatin® in Digestive Endocrine Tumors.- 8. VIPoma, Gastrinoma and Glucagonoma.- 9. Rebound Effect and Escape of Diarrhea Inhibition Using Sandostatin® in VIPoma Patients.- 10. Long-Term Treatment of VIPoma and Glucagonoma with Sandostatin®.- 111. Therapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell Carcinoma.- 12. Sandostatin® in the Treatment of Advanced Malignancies.- 13. Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with Sandostatin®.- 14. Sandostatin® and Gastroentero-pancreatic Endocrine Tumors -Therapeutic Characteristics.- 15. Consensus.- 16. Future Directions.
